Key role for liquid biopsy in the elimination of breast cancer surgery following neoadjuvant therapy

Affiliations

¹ Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. Electronic address: albertg@hadassah.org.il.
² Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
³ Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Free article

Comment

A Grinshpun et al. Ann Oncol. 2021 Mar.

Free article

. 2021 Mar;32(3):423.

doi: 10.1016/j.annonc.2020.12.002. Epub 2020 Dec 7.

¹ Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. Electronic address: albertg@hadassah.org.il.
² Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
³ Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

No abstract available

Conflict of interest statement

Disclosure The authors declare no conflicts of interest.

Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
Heil J, Kuerer HM, Pfob A, Rauch G, Sinn HP, Golatta M, Liefers GJ, Vrancken Peeters MJ. Heil J, et al. Ann Oncol. 2020 Jan;31(1):61-71. doi: 10.1016/j.annonc.2019.10.012. Ann Oncol. 2020. PMID: 31912797 Review.